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In recent years, the development of diagnostic methods based on metabolic imag-
ing has been aimed at improving diagnosis of prostate cancer (PCa) and perhaps at 
improving therapy. Molecular imaging methods can detect specific biological processes 
that are different when detected within cancer cells relative to those taking place in 
surrounding normal tissues. Many methods are sensitive to tissue metabolism; among 
them, positron emission tomography (PET) and magnetic resonance spectroscopic 
imaging (MRSI) are widely used in clinical practice and clinical research. There is a rich 
literature that establishes the role of these metabolic imaging techniques as valid tools 
for the diagnosis, staging, and monitoring of PCa. Until recently, European guidelines 
for PCa detection still considered both MRSI/MRI and PET/CT to be under evaluation, 
even though they had demonstrated their value in the staging of high risk PCa, and in 
the restaging of patients presenting elevated prostatic-specific antigen levels following 
radical treatment of PCa, respectively. Very recently, advanced methods for metabolic 
imaging have been proposed in the literature: multiparametric MRI (mpMRI), hyperpo-
larized MRSI, PET/CT with the use of new tracers and finally PET/MRI. Their detection 
capabilities are currently under evaluation, as is the feasibility of using such techniques 
in clinical studies.
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Prostate cancer (PCa) is the most common cancer in American men and in European elderly males 
(beyond 70 years of age). About one American man in seven and one European in eight will be 
diagnosed with PCa during his lifetime.
Although imaging has played a major role in PCa, many challenges still remain in the different 
phases of the disease: initial assessment during diagnosis, and re-assessment after radical treatment 
in cases of biochemical relapse and disease progression.
Currently, prostate biopsy remains the only procedure that provides a definitive diagnosis. The 
decision to perform a biopsy is based on information gathered from serum prostatic-specific antigen 
(PSA) level, digital rectal examination (DRE), ultra sound (US), and magnetic resonance (MR) 
imaging, along with family history of PCa. In the era of active, multimodal surveillance of PCa, 
clinicians are presented with challenge of improving the accuracy of biopsy during the diagnostic 
phase and detecting only the aggressive diseases that require treatment, to avoid overdiagnosis and 
overtreatment. Another significant challenge for imaging is PCa staging (1). Currently, lymph node 
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staging is based on surgery. A greater accuracy of imaging for 
staging may avoid unnecessary lymph nodes dissections reducing 
related complications (2).
Last but not least, accurate imaging during restaging of PCa 
following radical treatment presents an unsolved challenge. 
Currently, when conventional imaging detects disease relapse, 
PSA and PSA kinetics are too high and patients are often outside 
the window of curability. A greater accuracy of metabolic imaging 
techniques should improve the efficacy of salvage treatments (3).
CeLL MeTABOLiSM in PROSTATe
Prostate gland metabolism, in both its healthy and malignant 
forms, can be considered a “model” that has improved our under-
standing of the mechanisms and factors occurring when normal 
cells transform themselves into malignant cells. The metabolic 
profile of normal and cancerous prostate cells has provided a win-
dow into the carcinogenesis process, highlighting the importance 
of cellular metabolism in this process.
Studies of prostate metabolism clearly demonstrate that a 
combined knowledge of metabolic processes, genomics, and 
proteomics is fundamental for a proper understanding of the 
cancer process.
An expanded metabolic repertoire supports the reprogram-
ing of glucose, lipid, hormone, amino acid, and glycoprotein 
metabolic pathways during malignant transformation and tumor 
development in both the prostate gland and cancer cells in general.
Some of these pathways, especially those involving glucose, 
lipids, and amino acids, have been extensively studied by metabolic 
imaging. Normal prostate glucose pathways are characterized by 
low oxygen consumption (4) and minimal oxidation of citrate, 
both suggestive of a typical tumor cell metabolic profile (5), but 
caused by a normal accumulation of zinc that inhibits m-aconitase 
activity (6). The observed metabolic transformation in PCa is an 
increase in citrate oxidation of malignant cells, which has led to 
the hypothesis of increased m-aconitase activity compared to the 
normal epithelial cells. However, as highlighted by Singh et al. (7), 
proteomic analyses has shown that the level of m-aconitase does 
not change in cancerous prostate tissue, although the elevated 
zinc level inhibits its activity in normal tissue. As a consequence, 
in vivo non-invasive metabolic imaging has shown a high level 
of citrate in normal prostate gland that significantly decreases 
in regions of cancer associated with a significant choline (Cho) 
increase (8).
In fact, metabolic pathways of lipids, and in particular phos-
pholipids, are altered, as shown by in vivo 1H-MR spectroscopy 
imaging (MRSI) studies that detect elevated total Cho in regions 
of PCa and by ex vivo (9) and tissue (10) 1H-MR spectroscopy 
studies that detect the total Cho peak due to significant increases 
of free Cho, phosphocholine (PC), and glycerophosphocholine 
(GPC). The altered lipid pathway in PCa has also been studied 
using positron emission tomography (PET) imaging (11) with 
radiotracers, such as 11C-Cho (and 18F-Fluorocholine) and 
11C-acetate.
The amino acid metabolic pathway has also been studied by 
PET, exploiting the fact that amino acid transport is upregulated 
in PCa cells.
The metabolic peculiarities of prostate gland metabolism have 
driven the development of the techniques for its study in vivo.
IN VIVO TeCHniQUeS FOR MeTABOLiC 
iMAGinG
Metabolic imaging refers to a set of molecular imaging meth-
ods that provide direct information about tissue metabolism. 
Molecular imaging may be defined as the visualization, charac-
terization, and measurement of biologic processes at the molecu-
lar and cellular levels (12). Molecular imaging methods can 
detect specific biologic processes that change in cancer relative 
to surrounding normal tissue. Of course, it is desirable to have 
non-invasive instruments able to map the metabolism of various 
organs in vivo.
Many research methods are sensitive to tissue metabolism, 
and of these MRSI and PET are widely used in clinical practice 
and clinical research. Since the late 90s, both MRSI/MRI and 
PET/CT have been evaluated for PCa detection (8, 13, 14).
An MRSI exam is always associated with an MRI scan in order 
to have both metabolic and anatomical data. It is a non-invasive 
technique since non-ionizing radiation is used. Using MRSI, 
multiple metabolites can be spatially resolved in a single imag-
ing protocol with a spatial resolution that can be reduced below 
0.5 cm3; nevertheless with clinical systems, usually only a limited 
number of metabolites are present at concentrations that allow 
useful spatial mapping. This significantly limits the metabolic 
characterization of tumors. In prostate gland citrate, creatine, 
polyamine, and Cho-group resonances are detectable on 1.5- to 
3-T scanners and the (choline + creatine)/citrate ratio is known 
to increase with tumor aggressiveness (15, 16). In a systematic 
review and meta-analysis of the use of combined MRI and MRSI 
in PCa pooled sensitivity for the evaluation of primary tumor was 
68% (95% CI, 56–78%) with and pooled specificity 85% (95% CI, 
78–90%). Subdividing patient into low and high risk subgroups, 
the sensitivity was lower in low-risk patients [58% (46–69%) vs. 
74% (58–85%); p > 0.05] but higher for specificity [91% (86–94%) 
vs. 78% (70–84%); p < 0.01] (17).
Recently, developments in pulse sequences for MRSI have 
increased spectral resolution (18), and improved signal-to-noise 
(SNR) and volume selection (19).
Magnetic resonance spectroscopic imaging, unlike PET, 
detects static concentrations of endogenous molecules rather 
than tracer uptake. PET imaging is mostly used in association 
with a CT scan to sum up metabolic and anatomical information. 
A PET-CT scan involves exposure to ionizing radiation. PET is 
characterized by a high sensitivity in the detection of gamma 
radiation but with a spatial resolution which is not below a few 
millimeters. One of the drawbacks of PET for metabolic imaging 
is the absence of chemical information. The most commonly used 
tracer for PET imaging is [18F]-fluoro-2-deoxyglucose (FDG) 
but not all tumors consume glucose, so specific tracers have to be 
found for different tumors. The use of Cho radiotracers (11C-Cho 
and 18F-fluorocholine) and 11C-acetate is based on increased 
cellular membrane synthesis in PCa. Cho is overexpressed in 
cancer cells and is used for the synthesis of phosphatidylcholine, 
a prerequisite for cell membrane formation. Like Cho, acetate 
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is a substrate needed for lipogenesis and hence important for 
increased cell membrane synthesis during PCa. Just as with 
FDG, uptake level of lipogenesis tracers in benign tissue and PCa 
can overlap, determining the low specificity of these tracers for 
primary PCa detection (20). In a systematic review and meta-
analysis of 11C-acetate PET/CT in PCa, pooled sensitivity and 
pooled specificity for evaluation of primary tumor were 75.1% 
(95% CI: 69.8–79.8%) and 75.8% (95% CI: 72.4–78.9%), respec-
tively (21). 11C-Cho showed a sensitivity of 66% and specificity of 
81% for localization of primary PCa on a sextant histopathologic 
analysis (22). Although lipogenesis tracers present limitations for 
detection of primary PCa, they might be useful for a minority of 
newly diagnosed patients in whom distant metastatic disease is 
highly suspected on the basis of clinical data (serum PSA level 
>20  ng/ml, Gleason score 8–10, locally advanced tumor). In a 
systematic review, Evangelista et al. reported a sensitivity and a 
specificity of 19–90 and 88–98%, respectively, for detection of 
metastatic lymph nodes (2). These results are linked to a high 
false-positive rate due to inflammation and a high false-negative 
rate linked to micrometastatic lymph node disease undetectable 
by the majority of PET/CT scanners. More rigorous imaging trials 
are required to validate methods, and determine their sensitivity, 
to reduce the extreme variability of these results. The role of Cho 
PET/CT for restaging of biochemically recurrent PCa has been 
confirmed, particularly when the PSA level becomes elevated. 
One systematic review and meta-analysis including 19 selected 
studies with a total of 1555 patients revealed a pooled sensitivity 
of 85.6% and pooled specificity of 92.6% (23). In a recent study 
with a large cohort of patients, the accuracy of 11C-Cho PET/CT 
for the detection of sites of metastatic disease in PCa patients with 
biochemical relapse was confirmed. The authors also showed that 
in their series the PSA level was the main predictor of a positive 
scan with 1.16 ng/ml as the optimal cut-off value. They asserted 
that in the majority of positive scans they detected oligometastatic 
disease, potentially treatable with salvage therapies (3).
Other tracers have been and are currently being investigated 
(see Advanced Protocol and Perspectives) but only Cho and very 
recently 18F-FACBC have FDA approval for clinical use.
One of the latest molecular imaging modalities is hyperpolar-
ized 13C-MRSI. It combines the advantages of MRSI with an 
enormous gain in sensitivity in 13C detection due to the method 
of hyperpolarizing the molecules.
The dynamic nuclear polarization technique has been applied 
to 13C-MRSI (24): it is based on the transfer of polarization from 
the electron spins of paramagnetic centers embedded in a glassy 
frozen solution to neighboring nuclear spins (i.e., 13C nuclei 
of an informative biomolecule) through dipolar interactions. 
The solid solution is then rapidly dissolved and prepared for an 
intravenous injection. MRSI data must be obtained as rapidly as 
possible after dissolution because the enhancement is lost with 
the spin–lattice relaxation of the biomolecule. With hyperpolar-
ized 13C-MRSI, it is possible to monitor substrate uptake and 
the metabolism of endogenous biomolecules (25) by studying 
metabolic fluxes in vivo. Polarization methods, sequences, coils, 
and substrates (26, 27) have all been developed since 2007 with 
the aim of improving the accuracy of PCa evaluation.
CURRenT USe OF MeTABOLiC iMAGinG 
in CLiniCAL PRACTiCe
Figure 1A outlines the most common methods used for metabolic 
imaging in clinical practice. Their main technical characteristics 
are highlighted, divided into pros and cons. The utility of each 
technique for diagnosis, staging, and/or monitoring of therapy 
is indicated in vertical columns, subdivided into primary detec-
tion or recurrence. Figure 2A shows example images for these 
techniques.
Although an extensive literature shows how much these non-
invasive imaging techniques are used to assess PCa in Europe, 
guidelines for PCa staging still indicate MRSI/MRI and PET/
CT (32) as being under evaluation. The accuracy of MRSI/MRI 
aids in tumor localization within the peripheral zone, increasing 
the accuracy of extracapsular extension detection among less-
experienced readers, and decreasing inter-observer variability. 
Nevertheless, given difficulties in interpreting signal changes 
related to post-biopsy hemorrhage and inflammatory changes 
of the prostate, and the unquantifiable but significant inter- and 
intra-observer variability seen between both non-dedicated and 
dedicated radiologists, that may lead to under- or overestima-
tion of tumor presence and the local extent of disease, this 
technique is appropriate only for a limited number of cases. 
The overall accuracy of 11C-Cho PET in defining local tumor 
stage has been reported to be around 70% (33). PET tends to 
understage PCa, and has a limited value for making treatment 
decisions in patients with clinically localized PCa. Thus, rou-
tine clinical use of 11C-Cho PET cannot be recommended for 
detecting and staging primary PCa. By contrast, 11C-Cho PET/
CT is regarded as a well investigated modality for the restaging 
patients presenting with elevated PSA levels following radical 
treatment of PCa (34).
The ACRIN study on PCa localization by MRI and MRSI 
(35) showed that the accuracy of combined 1.5-T endorectal 
MR imaging–MR spectroscopic imaging for sextant localiza-
tion of peripheral zone PCa is equal to that of MR imaging 
alone. Nevertheless, many publications have showed that the 
combination of MRI and MRSI even in selected applications 
(such as diagnosis of cancer in men with more than one previous 
negative biopsy) really improves MRI performance (8, 21, 36, 
37). This disagreement with the ACRIN study is explained by the 
expertise of radiological staff (together with physicists, chemists, 
and biologists) in acquisition of MR spectra, in post-processing 
and by the close collaboration with urologists in approaching the 
diagnosis of each single patient. To overcome this methodological 
problem, fully automated procedures to assess MR spectra have 
been proposed; the classification capabilities of automated pat-
tern recognition approaches are equal to or better than manual 
methods (38, 39).
With regard to PET, its diagnostic power lies in its ability to 
stage disease, monitor treatment response, and detect recurrence, 
rather than in initial diagnosis (40); hence, PET is still prescribed 
only for equivocal cases and not for clinical routine.
It remains an open question whether, in the light of the exist-
ing literature and current diagnostic guidelines, MRI/MRSI and 
FiGURe 1 | Metabolic imaging in PCa detection. (A) Clinical applications of MRSI/MRI and PET/CT (standard tracers): pros and cons. (B) Advanced 
applications: hyperpolarized MRSI, mpMRI, PET/CT (new tracers), and PET/MRI: pros and cons. Abbreviations: MRSI, magnetic resonance spectroscopic imaging; 
MRI, magnetic resonance imaging; PET, positron emission tomography; CT, computed tomography; mpMRI, multiparametric MRI; P, primary tumor; R, recurrence; 
D, diagnosis; S, staging; M, monitoring.
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PET are needed to increase accuracy in PCa detection in clinical 
practice.
ADvAnCeD PROTOCOLS AnD 
PeRSPeCTiveS
Figure  1B outlines the most recent advanced approaches for 
metabolic imaging. As for Figure  1A, their main technical 
characteristics are highlighted, dividing between pros and 
cons. The utility of each technique for diagnosis, staging and/or 
monitoring of therapy is indicated in vertical columns. Figure 2 
shows example images of these advanced metabolic imaging 
approaches.
Multiparametric MRI (mpMRI) refers to the use of comple-
mentary MR techniques to improve the detection, characteriza-
tion and staging of PCa by T2-weighted MRI, MRSI, DTI, and 
dynamic contrast-enhanced MRI scans in the same session. The 
combination of such acquisitions gives anatomical, microstruc-
tural, functional, and metabolic information with the high spatial 
resolution of MRI. MpMRI data appears to be the most accurate 
imaging method for localizing primary PCa and staging primary 
or recurrent PCa (28, 41, 42). An mpMRI acquisition has no par-
ticular technical limitation apart from the use of a contrast agent 
for DCE imaging. Nevertheless, the challenge to the diffusion of 
mpMRI is the need for specialized clinical staff and the need to 
present data to clinical colleagues in a simple but meaningful way 
in spite of its complexity. Shared acquisition, post-processing, and 
interpretative protocols become essential. This requirement has 
inspired the definition of the PI-RAD score, specifically formal-
ized for predicting the presence of cancer by mpMRI findings 
from of T2w, T1w, DWI, and DCE acquisitions (43). The use of 
this score provides a combined evaluation of all functional and 
structural MR imaging scans; nevertheless a quantitative score 
for all techniques is still lacking. On the contrary, a quantitative 
evaluation for MRSI, which could be part of mpMRI protocol 
but is absent from the PI-RAD scoring system, has already been 
evaluated (44) and applied (14, 45).
Magnetic resonance spectroscopic imaging of hyperpolarized 
nuclei is a relatively new and sophisticated approach, which offers 
the possibility of monitoring tumor metabolism by the injection 
of labeled substrates and observation of their metabolic products 
without the use of ionizing radiation. Metabolic imaging with 
hyperpolarized 13C pyruvate, which provides information about 
tissue biochemistry, has been demonstrated to greatly increase 
the sensitivity of MRI in detecting PCa (46). Nevertheless, 
hyperpolarization is a highly demanding procedure due to both 
the process that drives nuclei to a non-stable but more sensitive 
condition and the rate of the exponential decay process, which 
limits acquisition time to a few tens of seconds. Thus, a number of 
hurdles must be overcome to transfer these methods to a clinical 
setting; the major one are technical, and regard the MR scanner 
and the polarizer, but there is the important matter of the safety 
of the substrate: to date no significant adverse effect have been 
observed in tolerability studies performed in test animals and 
the first application in human patients has shown no dose limit 
toxicity (29).
(A) MRSI/MRI and PET/CT. Transverse T2-weighted MR image (upper left) 
shows bilateral signal hypointensities and corresponding 3D MR 
spectroscopic spectra (lower left) show bilateral abnormalities [mean 
(Choline + Creatine)/Citrate ratio = 0.95 on right side and 1.10 on left] 
indicative of cancer, while corresponding PET/CT transverse images (upper 
right) do not show any relevant pathologic focal accumulation of 
11C-choline [background maximum SUV (standardized uptake value) = 2.5]. 
Corresponding pathologic specimen (hematoxylin–eosin stain; original 
magnification, ×1) (lower right) shows bilateral posterior adenocarcinoma 
(T3aNXMX, Gleason score 4 + 3) with right extracapsular extension (**). 
Reproduction with permission from Ref. (14) (RSNA). (B) mpMRI in a 
62-year-old man with PCa. Axial T2-weighted MR image (upper left) 
demonstrates a low-signal intensity focus (arrow) at right apex mid 
peripheral zone suspicious for PCa. Raw dynamic contrast-enhanced MR 
image (lower left) and ktrans (wash in) (upper middle) and kep (wash out) (lower 
middle) maps help localize tumor (arrow). Histopathologic slide at apex mid 
prostate level (upper right) confirms presence of tumor (Gleason score, 8) 
more anteriorly (red line), secondary to distortion and shrinkage of 
specimen. A, anterior; L, left; P, posterior; R, right. Reproduction with 
permission from Ref. (28) (RSNA). (C) 13C-hyperpolarized MRSI in a 
patient, who had a serum PSA of 4.5 ng/ml, was originally diagnosed with 
bilateral biopsy-proven Gleason grade 3 + 3 PCa, and received the highest 
dose of hyperpolarized [1-13C]pyruvate (0.43 ml/kg). On the left, an axial 
T2-weighted images and on the right the corresponding spectral array with 
the area of putative tumor highlighted by pink shading. A region of tumor 
was observed on the T2-weighted images (red arrows). From Ref. (29) 
(Nelson SJ, Kurhanewicz J, Vigneron DB, Larson PE, Harzstark AL, 
Ferrone M, et al. Metabolic imaging of patients with prostate cancer using 
hyperpolarized [1-13C]pyruvate. Sci Transl Med (2013) 5(198):198ra108. 
Reprinted with permission from AAAS.) (D) Coronal PET (left) and CT fused 
(right) anti-18F-FACBC images of 63-year-old male patient with 
pathologically proven bilateral prostate carcinoma (arrows on the left). Note 
little bladder activity (white arrows on the right). This research was originally 
published in JNM (30). Schuster et al.© by the Society of Nuclear Medicine 
and Molecular Imaging, Inc. (e) PET/MRI fusion imaging in high-grade PCa. 
Specific image information derived from 11C-choline PET (upper middle), 
ADC (apparent diffusion coefficient) DWI (upper right), hematoxylin–eosin 
(HE) histology (lower left), and parametric fusion PET/MRI using PCHOL/
ADC* (lower right) is coregistered with transaxial T2-weighted MRI (upper 
right). Color bars indicate 11C-choline SUV (standardized uptake value) 
(upper middle), PCHOL/ADC* (lower right), and inverted ADC (upper right). 
Zoomed registered HE histology slice is shown for increased clarity (lower 
left). At histology, Gleason 4 + 3 lesion is located in left lobe of prostate (red 
arrows) in peripheral and central zone, which is identified on registered 
imaging, whereas additional low-volume Gleason 3 + 3 lesion in right lobe is 
not identified (blue arrows) *
+
PCHOL /ADC
11C Choline SUV
ADC 0.001
=
- . This 
research was originally published in JNM. Park et al. (31) © by the Society of 
Nuclear Medicine and Molecular Imaging, Inc.
FiGURe 2 | example images showing advanced metabolic imaging 
approaches to PCa detection.  
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In PET imaging, several promising radiotracers are currently 
being investigated for the evaluation of PCa but not based on the 
detection of glucose or fatty acid metabolism since glucose and 
lipogenesis tracers have demonstrated limitations for detection 
of primary PCa. These new radiotracers aim to monitor amino 
acid metabolism (anti-18F-FACBC), DNA synthesis, and the 
expression and activity levels of a variety of receptors, enzymes, 
and other cancer-specific and non-specific biomarkers.
The radiotracer 1-amino-3-florine-18-florocyclobutane-
1-carboxylic acid (18-FACBC) exploits the fact that amino acid 
transport is upregulated in PCa cells. The low urinary excretion 
of this radiotracer also allows 18-FACBC uptake in malignant (Continued)
FiGURe 2 | Continued
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tumor cells to be detected more accurately. Few papers have 
been published on the role of 18F-FACBC for the evaluation of 
primary or recurrent PCa. Schuster et al. compared the diagnostic 
performance of 18F-FACBC and 111In-capromab in 93 patients 
reporting a higher accuracy for 18F-FACBC and an upstaging 
of recurrent disease in at least 25% of patients (30). Nanni et al. 
recently confirmed the higher accuracy of 18F-FACBC compared 
to 11C-Cho in restaging of PCa, particularly in patients with low 
PSA levels (<1 ng/ml) (47).
To date, about 1000 patients have been studied with 
68Ga-PSMA (prostate-specific membrane antigen) in different 
clinical indications, such as initial staging and restaging of disease 
and in comparison with other common radiopharmaceutical 
agents for PET imaging, such as radiolabeled Cho. PSMA is a 
membrane glycoprotein with an extensive extracellular domain, 
a transmembrane segment, and an intracellular domain. PSMA 
is normally expressed in epithelial cells within the prostate 
and is strongly upregulated at all stages of PCa. An increase in 
PSMA expression has been associated with tumor aggressiveness, 
metastasis, and disease recurrence, providing a rational target for 
ligand–receptor-based imaging and therapy. Two groups have 
demonstrated that 68Ga-PSMA PET/CT is superior to 18F-Cho 
PET/CT and conventional imaging modalities (48, 49). Eiber et al. 
evaluated the accuracy of 68Ga-PSMA PET/CT in 248 patients 
with biochemical relapse and showed a patient-based detection 
rate of 89.5% with a detection rates for PSA levels of ≥2, 1 to <2, 
0.5 to <1, and 0.2 to <0.5 ng/ml were 96.8, 93.0, 72.7, and 57.9%, 
respectively (50). Clinically, it is very important that 68Ga-PSMA 
PET/CT has a high detection rate for low values of PSA allowing 
the site of recurrence to be detected within the windows of cur-
ability. Further studies are required to confirm these data.
Finally, the role of PET/MR has not yet been established: it 
offers the possibility of enhancing patient convenience by provid-
ing a single metabolic imaging session to replace separate MRI 
and PET/CT scans, reducing patient anxiety, total scan time, and 
recalls for repeated scanning. Although preliminary results are 
encouraging (31, 51, 52), it is unknown whether this sophisti-
cated modality will demonstrate the high performance of MRI in 
the staging of the primary cancer and the metabolic profiling of 
lesions offered by 11C-Cho PET. It would be interesting to evalu-
ate the inclusion of MRSI in PET/MR protocols.
In conclusion, the challenge for researchers is to improve 
the accuracy of metabolic imaging techniques for the diagnosis 
of PCa, and in consequence to allow improvements in therapy. 
MpMRI, 13C hyerpolarization for in  vivo 13C-MRI, new trac-
ers for PET scan, and the combination of PET with MRI are all 
new metabolic imaging tools that show promise in meeting this 
challenge.
However, all the cited advanced metabolic techniques have 
to be evaluated considering both their potential capabilities and 
their clinical applicability. The most promising technique can 
then be integrated in multiparametric protocols that must be 
standardized if they are to be applied in a clinical context.
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